Related Experiment Video
Updated: Dec 14, 2025

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Temporin A and Bombinin H2 Antimicrobial Peptides Exhibit Selective Cytotoxicity to Lung Cancer Cells
Lucy Swithenbank1, Phillipa Cox1, Llinos G Harris1
1Swansea University Medical School, Institute of Life Science, Swansea University, Swansea SA2 8PP, UK.
Background:
Recently, antimicrobial peptides (AMPs) have been investigated for their use in cancer therapy. They have been reported to selectively target and kill cancer cells whilst leaving normal healthy cells unaffected. Certain Anura AMPs have expressed selective cytotoxicity against tumour cells.
Aim:
To test the potential of Anura AMPs bombinin H2, bombinin H4, temporin A, and temporin L for use as therapeutic agents for non-small cell lung carcinoma (NSCLC).
Methods:
Cytotoxic effects on NSCLC cell lines A549 and Calu-3 and normal epithelial cell line Beas-2B were tested using the CellTox Green Cytotoxicity Assay. Their haemolytic effects on human erythrocytes were also tested for their clinical relevance. Cell membrane profiling, using MALDI-TOF, was performed to ascertain if membrane characteristics of the NSCLC and Beas-2B cell lines may contribute to the AMPs mode of action.
Results:
Bombinin H4 (100-1.5 μM, p < 0.05) and temporin A (100-50 μM, p < 0.05) showed selective cytotoxicity towards the NSCLC cell lines. Furthermore, they exhibited low levels of haemolytic activity (bombinin H4, 0.061%; temporin A, 0.874%) comparable to untreated cells. Cell membrane profiling showed the phospholipid composition of normal epithelial cell line Beas-2B to be divergent from the cancerous cell lines. However, there was an overlap in the phospholipid profiles of the NSCLC cell lines supporting the hypothesis that the AMPs may have a selective affinity via the membrane composition of cancerous cell lines.
Conclusion:
These results suggest that bombinin H4 and temporin A show potential for application in lung cancer therapies. Further in vitro and in vivo studies are required to develop a greater understanding of their use as anticancer agents.
Insights
Antimicrobial peptides (AMPs) bombinin H4 and temporin A show promise for treating non-small cell lung carcinoma (NSCLC). These peptides selectively kill cancer cells with minimal impact on healthy cells, suggesting potential therapeutic applications.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Antimicrobial peptides (AMPs) are explored for cancer therapy due to their selective cancer cell targeting.
- Certain Anura AMPs demonstrate selective cytotoxicity against tumor cells.
Purpose of the Study:
- To evaluate bombinin H2, bombinin H4, temporin A, and temporin L as potential therapeutic agents for non-small cell lung carcinoma (NSCLC).
Main Methods:
- Cytotoxicity assays (CellTox Green) were performed on NSCLC cell lines (A549, Calu-3) and a normal epithelial cell line (Beas-2B).
- Hemolytic activity on human erythrocytes was assessed for clinical relevance.
- MALDI-TOF was used for cell membrane profiling to understand AMPs' mode of action.
Main Results:
- Bombinin H4 and temporin A exhibited selective cytotoxicity against NSCLC cell lines.
- Both peptides showed low hemolytic activity, comparable to controls.
- Differential phospholipid profiles between cancer and normal cells suggest a mechanism for selective AMP targeting.
Conclusions:
- Bombinin H4 and temporin A show potential for NSCLC therapy.
- Further in vitro and in vivo studies are needed to fully understand their anticancer potential.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Drugs that Destabilize Microtubules
Drugs that Stabilize Microtubules
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

